Overview of technological platforms in candidate vaccines against SARS-CoV-2
Platform | Advantage | Vaccine type | Vaccine name | Developers | Stage |
Inactivated | Well established manufacturing process | Purified whole SARS-CoV-2 components | CoronaVac | Sinovac Life Sciences, Beijing, China | Phase III |
New Crown COVID-19 | Wuhan Institute of Biological Products/Sinopharm | Phase III | |||
BIBIBP-CorV | Beijing Institute of Biological Products/Sinopharm | Phase III | |||
Nucleic acid | Rapid and low cost manufacturing | Lipid-encapsulated mRNA | mRNA1273 | Moderna/NIAID | Phase III |
bNT162b2 | BioNTech/Fosun Pharma/Pfizer | Phase III | |||
Self-amplifying mRNA | LNP-nCoVsaRNA | Imperial College London | Phase I | ||
Plasmid DNA with medical device | INO-4800 | Inovio Pharmaceuticals/ International Vaccine Institute | Phase I/II | ||
Viral vector | Robust cellular and humoral vaccine immunity | Chimpanzee adenovirus (ChAd) | ChAdOx1 nCoV-19 | AstraZeneca/University of Oxford | Phase III |
Human adenovirus type 5 | Ad5-nCoV | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase III | ||
Human adenovirus type 26 | Ad26.COV2-S | Janssen Pharmaceutical companies | Phase III | ||
Vesicular stomatitis virus | IIBR-100 | Israel Institute for Biological Research | Phase I/II |
Adopted from Ura et al.51
mRNA, messenger RNA.